Navigation Links
MPM Capital Leads Investment in Proteon Therapeutics
Date:3/5/2009

Dr. Steven St. Peter Named to Proteon Board of Directors

KANSAS CITY, Mo., March 5 /PRNewswire/ -- MPM Capital, one of the world's largest life sciences-dedicated venture capital investors, announced today that it is the lead investor in a $38 million Series B equity financing of Proteon Therapeutics. In addition, Dr. Steven St. Peter, Managing Director of MPM Capital, has been named to the Proteon Therapeutics Board of Directors.

Proteon recently initiated a Phase 1/2 clinical trial of its lead product, PRT-201. PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis.

"MPM continues to be very impressed with Proteon and the progress that the company has made," said Dr. Steven St. Peter. "In addition, this marks the first investment by MPM in a company with a substantial Kansas City presence. We have long followed the positive developments in the Kansas City area life sciences sector, and this investment affirms our view that attractive opportunities originate there."

Over the last several years, Dr. Steven St. Peter has worked informally with the Kansas City Area Life Sciences Institute in an advisory capacity. In addition, he currently serves as a member of the Kansas Bioscience Authority's Heartland BioVentures Advisory Board. Originally from Wichita, Dr. St. Peter has a B.A. in Chemistry from the University of Kansas. He completed his Doctor of Medicine at Washington University in St. Louis and his residency and fellowship at the Hospital of the University of Pennsylvania.

"Proteon is very pleased to have attracted the interest of MPM Capital, one of the world's premier healthcare venture capital firms," said F. Nicholas Franano, M.D., Chief Scientific Officer and founder of Proteon Therapeutics. "MPM's understanding of the life sciences industry makes them an ideal investor. In addition, I have known and worked with Steven St. Peter for over 20 years and am excited about the contribution he will make to our board of directors and the future direction of our company."

In addition to MPM Capital, the other new investor in this round of financing is the Vectis Healthcare & Life Sciences Fund. MPM and Vectis have a strong and deep relationship.

Tim Noyes, CEO of Proteon, said, "Proteon welcomes these additions to our already strong investor base. This financing will allow us to fund very significant clinical development in a field that needs better solutions."

About MPM Capital

MPM Capital is one of the world's largest dedicated investors in the life sciences. With offices in Boston and San Francisco, the firm manages committed capital in excess of $2 billion. MPM Capital has a deep and experienced team capable of investing from early-stage to late-stage which positions it to invest across the full spectrum of healthcare innovation. For additional information, visit www.mpmcapital.com

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, visit www.proteontherapeutics.com


'/>"/>
SOURCE MPM Capital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: